Key result
Oral rivaroxaban 20 mg once daily was noninferior to dose-adjusted warfarin in the prevention of stroke and non-central nervous system systemic embolism, with a comparable risk of bleeding.
Why the study?
Does rivaroxaban prevent stroke and systemic embolism compared to warfarin in patients with nonvalvular atrial fibrillation?
Population
Patients with nonvalvular atrial fibrillation (moderate- to high-risk)
Comparison
Rivaroxaban 20-mg oral once daily vs Dose-adjusted warfarin
Design
Review
Authors
Loading...
May support rivaroxaban as warfarin alternative in nonvalvular AF; leaves open head-to-head trials versus other NOACs.
Does rivaroxaban prevent stroke and systemic embolism compared to warfarin in patients with nonvalvular atrial fibrillation?
Rivaroxaban is a safe and effective alternative to warfarin for stroke prophylaxis in patients with nonvalvular atrial fibrillation, without the need for routine coagulation monitoring.
Carag et al. (2012) conducted a review in Atrial fibrillation. Rivaroxaban vs. Dose-adjusted warfarin was evaluated on Stroke and non-central nervous system systemic embolism. Oral rivaroxaban 20 mg once daily was noninferior to dose-adjusted warfarin in the prevention of stroke and non-central nervous system systemic embolism, with a comparable risk of bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: